Quick Answer
Chemomab Therapeutics Ltd. reported Cash And Cash Equivalents At Carrying Value of $7.56 million for the year ending 2025.
- Chemomab Therapeutics Ltd. showed an increase of +24.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Chemomab Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Chemomab Therapeutics Ltd.'s Cash And Cash Equivalents At Carrying Value has grown by 0.6%.
- Historical annual values: Fiscal year 2025: $7.56 million | Fiscal year 2024: $6.07 million | Fiscal year 2023: $9.29 million | Fiscal year 2022: $13.52 million | Fiscal year 2021: $15.19 million | Fiscal year 2020: $11.67 million | Fiscal year 2019: $17.58 million | Fiscal year 2018: $7.52 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: